Although the ADRENAL trial was a multicenter, international study, the lion's share of the participants were in Australia (~70%). Moreover, the APROCCHS trial only studied patients in France. Both of these trials took a remarkable coordination effort, yielded intriguing findings, and were monumental accomplishments. However, are their results generalizable to the rest of the world?
Recently, there have been a few key articles highlighting our current understanding of the global burden of sepsis. Unfortunately, it showed we know a lot about the burden in high-income countries, but have almost no data on the epidemiology of sepsis in low and middle-income countries [1, 2]. These countries likely suffer a high burden of disease. Fortunately, sepsis is now being recognized as a global health priority by the WHO with new resolutions underway (3). Do you think the results of these trials be generalizable to low and middle-income countries?
1. Fleischmann et al. (2016). Assessment of global incidence and mortality of hospital-treated sepsis. current estimates and limitations. American Journal of Respiratory and Critical Care Medicine, 193(3), 259-272. doi:10.1164/rccm.201504-0781OC [doi]
2. Finfer, S., & Machado, F. R. (2016). The global epidemiology of sepsis. does it matter that we know so little? American Journal of Respiratory and Critical Care Medicine, 193(3), 228-230. doi:10.1164/rccm.201510-1976ED [doi]
3. Reinhart et al. Recognizing sepsis as a global health priority — A WHO resolution. NEJM.
Easy one-click social registrationIs this safe?
We only receive the minimum information necessary to verify your account. We never get access to your friends/contacts or your profile, and we never post on your behalf. Your social account is used for logging in only.ORRegister via email
Send me updates on this Contest
In order to ensure a fair voting process and to make sure that no one votes more than once, we ask that you register either with a social networking account (easiest, only requires one click) or by registering with your email address (this will require you to click on a verification email that we will send you).
You only need to register once.